Effects of EGFR inhibitor AG 1478 on MDA-MB-231 and MCF-7 breast cancer cells
Abstract
In this current study, antiproliferative effect of EGFR inhibitor AG1478 was investigated in human breast cancer cell lines. MDA-MB-231 and MCF-7 cell lines were used respectively as triple negative breast cancer and Luminal A breast cancer model. To this end cell viability, cell index values by xCELLigence Real‐Time Cell Analysis DP instrument and mitotic index analysis were used. The results of the current study showed that AG1478 had cytostatic effects on both of cell lines. The IC50 concentration was determined as 50 µM for MDA-MB-231 and 20 µM for MCF-7 cell line. IC50 concentration was used for mitotic index parameter. IC50 concentrations decreased the mitotic index values of both of cell lines. There were significant differences between the control and the experimental groups (p<0.05). The results of the present study suggest that AG1478 may serve as a promising treatment option for breast cancer.
Keywords
In vitro, Breast cancer, MDA-MB-231, MCF-7, EGFR inhibitor.
Project Number
FYL-2016-21025
References
- [1] Russo J., Russo I.H., Development of The Human Breast, Maturitas, 49(1) (2004) 2-15.
- [2] Bahreyni A., Samani S.S., Rahmani F., Behnam‐Rassouli R., Khazaei M., Ryzhikov M. et al., Role of Adenosine Signaling in The Pathogenesis of Breast Cancer, Journal of Cellular Physiology, 233(3) (2018) 1836-1843.
- [3] Topçul M., Çetin İ., Breast Cancer, Cancer: Disease of the Age, In: (Ed.) Ahmed M El-Sharkawy, Chapter 19, OMICS Group eBooks, Foster City, USA, (2015) 1-21.
- [4] Board P.C.G.E., Genetics of Breast and Gynecologic Cancers (PDQ®), (2016).
- [5] Schulz W.A., Breast Cancer, In: Schulz WA (Ed.). Molecular Biology of Human Cancers, Springer, Germany, (2005) 357-382.
- [6] Weber G.F., Epithelial Tumors, In: Weber GF (Ed.). Molecular Mechanisms of Cancer, Springer, USA, (2007) 441-524.
- [7] Tryggvadottir L., Olafsdottir E.J., Gudlaugsdottir S., Thorlacius S., Jonasson J.G., Tulinius H. et al., BRCA2 Mutation Carriers, Reproductive Factors and Breast Cancer Risk, Breast Cancer Research, 5(5) (2003) R121.
- [8] Narod S.A., Modifiers of Risk of Hereditary Breast and Ovarian Cancer, Nat. Rev. Cancer, 2 (2002) 113-123.
- [9] Vidarsson H., Mikaelsdottir E.K., Rafnar T., Bertwistle D., Ashworth A., Eyfjord J.E. et al., BRCA1 and BRCA2 Bind Stat5a and Suppress Its Transcriptional Activity, FEBS Letters, 532(1-2) (2002) 247-252.
- [10] Yarden Y., Ullrich A., Growth Factor Receptor Tyrosine Kinases, Annu Rev Biochem., 57 (1988) 443-478.